Eduard Vrdoljak

Eduard Vrdoljak

Auto-generated profile, based on publicly available information

Eduard Vrdoljak

Clinical Hospital Centre Split

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Croatian Medical Journal
Verified
Journal Article
Open access
EVEduard Vrdoljak
Eduard Vrdoljak
MWMarek Z. Wojtukiewicz
Marek Z. Wojtukiewicz
TPTadeusz Pienkowski
Tadeusz Pienkowski
GBGyorgy Bodoky
Gyorgy Bodoky
PBPeter Berzinec
Peter Berzinec
F(for South Eastern European Research Oncology Group (SEEROG)
for South Eastern European Research Oncology Group (SEEROG)
To collect cancer epidemiology data in South Eastern European countries as a basis for potential comparison of their performance in cancer care. The South Eastern European Research Oncology Group (SEEROG) collected and analyzed epidemiological data on incidence and mortality that reflect cancer management in 8 countries – Croatia, Czech Republic, Hungary, Romania, Poland, Slovakia, and Serbia and Montenegro in the last 20-40 years. The most common cancer type in men in all countries was lung cancer, followed by colorectal and prostate cancer, with the exception of the Czech Republic, where prostate cancer and colorectal cancer were more common. The most frequent cancer in women was breast cancer followed by colorectal cancer, with the exceptions of Romania and Central Serbia where cervical cancer was the second most common. Cancer mortality data from the last 20-40 years revealed two different patterns in men. In Romania and in Serbia and Montenegro, there was a trend toward an increase, while in the other countries mortality was declining, after increasing for a number of years. In women, a steady decline was observed over many years in the Czech Republic, Hungary, and Slovakia, while in the other countries it remained unchanged. There are striking variations in the risk of different cancers by geographic area. Most of the international variation is due to exposure to known or suspected risk factors which provides a clear challenge to prevention. There are some differences in incidence and mortality that cannot be explained by exposure to known risk factors or treatment availabilities.

1 November 2006 in Gynecologic Oncology
Verified
Journal Article
Closed access
EVEduard Vrdoljak
Eduard Vrdoljak
TOTomislav Omrčen
Tomislav Omrčen
ŽNŽana Saratlija Novaković
Žana Saratlija Novaković
TJTihana Boraska Jelavić
Tihana Boraska Jelavić
TPTomislav Prskalo
Tomislav Prskalo
WHWolfgang Hamm
Wolfgang Hamm

1 February 2011 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
EVEduard Vrdoljak
Eduard Vrdoljak
TOTomislav Omrčen
Tomislav Omrčen
MBMarijo Boban
Marijo Boban
AHAndina Hrabar
Andina Hrabar
The relative survival of elderly patients with metastatic colorectal cancer (mCRC) is generally worse than that of younger patients because of more advanced stage at presentation, comorbidity and reduced use of optimal therapy. We conducted a prospective phase II trial of the combination of bevacizumab and capecitabine in elderly patients with mCRC. In total 41 patients aged more than or equal to 70 years with mCRC, who had not received chemotherapy earlier for metastatic disease, were enroled. Patients received capecitabine (1000 mg/m2 twice daily on days 1–14) and bevacizumab (7.5 mg/kg of body weight on day 1). The treatment cycles were repeated every 3 weeks. The overall response rate was 65%, including 13% of patients with a complete response and 53% of patients with a partial response. A further 13% of patients maintained stable disease. The median progression-free survival was 11.5 months and the median overall survival was 21.2 months. Despite the advanced age of participants, the rate of bevacizumab-related and capecitabine-related adverse events was consistent with that reported earlier in the general mCRC population. The combination of bevacizumab and capecitabine is effective and has a favourable tolerability profile and should be considered as an option for the initial treatment of mCRC in elderly patients.

21 December 2011 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
EVEduard Vrdoljak
Eduard Vrdoljak
TCTudor Eliade Ciuleanu
Tudor Eliade Ciuleanu
GKGalina Kharkevich
Galina Kharkevich
JMJozef Mardiak
Jozef Mardiak
MMMichal Mego
Michal Mego
LTLaszlo Torday
Laszlo Torday
Introduction: Belarus, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Republic of Moldova, Romania, Russian Federation, Serbia, Slovakia, Slovenia and the Ukraine represent a collection of Central and Eastern European (CEE) countries in which the epidemiology and treatment of cancer varies greatly between and within countries. Current challenges include non-adherence to current treatment guidelines, restrictions in access and reimbursement for new therapies, and a lack of basic oncology programs. Metastatic renal cell carcinoma (mRCC) is a malignancy with historically poor prognosis. In CEE countries, the incidence and mortality rates of mRCC are among the highest in the world. Fortunately, mRCC represents a cancer for which a number of new targeted therapies have recently demonstrated benefit, resulting in new evidence-based treatment guidelines. Incorporating these mRCC treatment recommendations into the routine care of patients with mRCC in CEE countries would represent a major step forward for cancer care in this region. Areas covered: This review discusses the unique challenges faced by the aforementioned Eastern European countries in the treatment of metastatic renal cell cancer, in an attempt to assist health-care providers in providing the best care possible for their European patients. Expert opinion: Despite a wealth of clinical trial data supporting the use of targeted therapies for first-line treatment of mRCC, cytokine-based immunotherapy is still used in some of these European countries. With implementation and adherence to existing guidelines, treatment can be clinically and economically optimized in patients with mRCC from this region.

1 June 2013 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
EVEduard Vrdoljak
Eduard Vrdoljak
BRBrian Rini
Brian Rini
MSManuela Schmidinger
Manuela Schmidinger
TOTomislav Omrčen
Tomislav Omrčen
LTLaszlo Torday
Laszlo Torday
ASAvishay Sella
Avishay Sella
Skeletal involvement is common in patients with renal cell carcinoma (RCC): ∼30% of patients with metastatic RCC (mRCC) will develop bone metastases. Inhibition of vascular endothelial growth factor (VEGF) has been pursued as a therapeutic target in the treatment of metastatic clear-cell RCC (m-ccRCC). Tyrosine kinase inhibitors (TKIs), such as sunitinib, pazopanib, sorafenib, and the monoclonal antibody bevacizumab, became the therapy of choice for patients with m-ccRCC. Besides the undisputed efficacy of TKI in the treatment of m-ccRCC, the problem of metastatic bone disease still remains. There is evidence that the presence of bone metastases in m-ccRCC patients has a significant and clinically relevant negative impact on survival and potentially on the outcome of VEGF-targeted therapy. Also, a relatively common practice in the treatment of such patients is bone-directed therapy with bisphosphonates (BPs). Recent evidence shows a potentially synergistic effect on efficacy but also the potential for increased toxicity of combining TKIs and BPs. This review article highlights the importance of this subject and aims to facilitate further research and optimize the treatment of this important and common group of RCC patients.

28 February 2009 in The Breast
Verified
Journal Article
Open access
PDF file
OOOlaf Ortmann
Olaf Ortmann
TCTanja Cufer
Tanja Cufer
JDJ. Michael Dixon
J. Michael Dixon
NMNicolai Maass
Nicolai Maass
PMPaolo Marchetti
Paolo Marchetti
HWHans Wildiers
Hans Wildiers
Adjuvant treatment with aromatase inhibitors (AIs) improves outcomes in postmenopausal women with hormone-sensitive early breast cancer compared with tamoxifen. However, AIs should not be used in premenopausal women because they can paradoxically increase estrogen secretion and may therefore stimulate tumor progression. In perimenopausal women undergoing treatment for breast cancer, it can be difficult to determine true menopausal status because adjuvant chemotherapy, tamoxifen, and gonadotropin-releasing hormone analogues can induce transient (or permanent) ovarian suppression. How can one determine whether these women are truly postmenopausal and therefore candidates for AI therapy? A panel of experts in the field of endocrine therapy in breast cancer met in Dubrovnik, Croatia, on October 23, 2006, to discuss this clinical dilemma. This report summarizes the conclusions and recommendations that arose from this discussion.